RNTX Rein Therapeutics Inc.
Price (delayed)
$2.25
Market cap
$48.75M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.15
Enterprise value
$31.07M
Highlights
The EPS is down by 11% year-on-year but it is up by 4% since the previous quarter
Rein Therapeutics's net income has plunged by 126% YoY and by 16% from the previous quarter
RNTX's quick ratio has shrunk by 58% YoY and by 30% QoQ
Key stats
What are the main financial stats of RNTX
Market
Valuations
Earnings
Shares outstanding
21.67M
Market cap
$48.75M
Enterprise value
$31.07M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.51
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$29.61M
Net income
-$29.24M
EBIT
-$29.24M
EBITDA
-$29.13M
Free cash flow
-$27.87M
Per share
Balance sheet
Liquidity
EPS
-$3.15
EPS diluted
-$3.15
Free cash flow per share
-$1.29
Book value per share
$4.4
Revenue per share
$0
TBVPS
$0.86
Total assets
$104.22M
Total liabilities
$8.99M
Debt
$0
Equity
$95.23M
Working capital
$13.03M
Debt to equity
0
Current ratio
3.3
Quick ratio
3.12
Net debt/EBITDA
0.61
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-27.9%
Return on equity
-30.3%
Return on invested capital
N/A
Return on capital employed
-29.7%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
RNTX stock price
How has the Rein Therapeutics stock price performed over time
Intraday
2.74%
1 week
-9.64%
1 month
-1.32%
1 year
-51.86%
YTD
-2.17%
QTD
-2.17%
Financial performance
How have Rein Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$29.61M
Net income
-$29.24M
Gross margin
N/A
Net margin
N/A
Rein Therapeutics's net income has plunged by 126% YoY and by 16% from the previous quarter
The operating income has dropped by 116% year-on-year and by 16% since the previous quarter
Growth
What is Rein Therapeutics's growth rate over time
Valuation
What is Rein Therapeutics stock price valuation
P/E
N/A
P/B
0.51
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS is down by 11% year-on-year but it is up by 4% since the previous quarter
RNTX's P/B is 62% below its 5-year quarterly average of 1.3
Rein Therapeutics's equity has decreased by 6% QoQ
Efficiency
How efficient is Rein Therapeutics business performance
The ROE has soared by 67% YoY and by 9% from the previous quarter
The ROA has soared by 64% YoY and by 9% from the previous quarter
Dividends
What is RNTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for RNTX.
Financial health
How did Rein Therapeutics financials performed over time
RNTX's quick ratio has shrunk by 58% YoY and by 30% QoQ
RNTX's current ratio has dropped by 58% year-on-year and by 30% since the previous quarter
The debt is 100% smaller than the equity
Rein Therapeutics's equity has decreased by 6% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.